TITLE:
A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.

CONDITION:
Breast Cancer

INTERVENTION:
ABT-751

SUMMARY:

      The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how
      long the tumor shrinkage can be maintained in patients with breast cancer after having had
      taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will
      be off drug for 7 days before starting the next cycle of drug.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          -  Stage IIIB or IV breast cancer.

          -  Recurrent tumor after or while on taxane therapy (taxol or taxotere).

          -  Able to tolerate normal activities of daily living.

          -  Adequate bone marrow, kidney and liver function.

        Exclusion Criteria

          -  Pregnant or breast feeding.

          -  No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the
             start of ABT-751 administration.
      
